Tactile Systems Acquires LymphaTech for $6.8M and Posts 21% Q4 Sales Growth
Tactile Systems paid $6.8 million upfront for LymphaTech, gaining handheld lymphedema measurement technology with milestone-based earnouts. Fourth-quarter sales rose 21% to $103.59 million with Q4 EPS of $0.46, and fiscal 2026 revenue is now forecast at $357–365 million.
1. Acquisition Details
Tactile Systems acquired LymphaTech for $6.8 million upfront plus milestone-based earnouts to expand its lymphedema diagnostic portfolio. LymphaTech’s handheld device measures fluid volume and circumference for precise treatment monitoring.
2. Q4 Financial Results
In Q4, sales rose 21% year-over-year to $103.59 million and EPS reached $0.46, beating prior-year EPS of $0.44. Gross profit increased 26% to $81 million, operating income surged to $18.8 million, and adjusted EBITDA climbed to $22.9 million.
3. Fiscal 2026 Outlook
For fiscal 2026, management raised revenue guidance to $357 million–$365 million and forecast adjusted EBITDA between $49 million and $51 million, up from prior consensus of approximately $347.94 million.
4. Stock Performance and Analyst Ratings
Share price jumped over 23% premarket to a 52-week high, trading well above the 20-day and 100-day moving averages. Analysts maintain buy ratings with price targets lifted to as high as $38.